- Previous Close
2.0900 - Open
2.0600 - Bid --
- Ask --
- Day's Range
1.8000 - 2.0600 - 52 Week Range
1.6200 - 3.6100 - Volume
10,091 - Avg. Volume
6,666 - Market Cap (intraday)
47.976M - Beta (5Y Monthly) -1.02
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3700 - Earnings Date Nov 12, 2024 - Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.00
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.
www.anebulo.comRecent News: ANEB
View More
Performance Overview: ANEB
Trailing total returns as of 9/25/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ANEB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ANEB
View MoreValuation Measures
Market Cap
47.98M
Enterprise Value
42.83M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
9.62
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-57.90%
Return on Equity (ttm)
-104.28%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-9.35M
Diluted EPS (ttm)
-0.3700
Balance Sheet and Cash Flow
Total Cash (mrq)
5.15M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.51M
Research Analysis: ANEB
View MoreCompany Insights: ANEB
ANEB does not have Company Insights